Vascular endothelial growth factor (VEGF)-C - a potent risk factor in children diagnosed with stadium 4 neuroblastoma. by Nowicki, Michal et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2008:46(4): 493 (493-499) 
doi: 10.2478/v10042-008-0067-7
Introduction
The vascular endothelium represents a dynamic struc-
ture on the border between circulating blood and the
surrounding tissue [1]. Terminally differentiated,
mature endothelial cells are regarded to have a low
proliferative potential. Thus, endothelial repair and
angiogenesis, including neovascularization, evidently
need the support of other angiogenic cells. These are
derived from the bone marrow and have been termed
endothelial progenitor cells (EPCs) [1-6]. They have
properties of embryonal angioblasts and are charac-
terised by expression of 3 surface markers; CD133,
CD34 and vascular endothelial growth factor receptor
(VEGFR)-2 [2-5]. The process of intra-vascular matu-
ration: angioblasts – early EPC – late EPC which is
controlled by serum VEGF-A165 [2-6], involves grad-
ual loss of their progenitor properties (CD133) and
start expression of endothelial markers like VE-cad-
herin, nitric oxide synthase and von Willebrand factor
[1]. Late EPCs still express VEGFR-2 and CD34 but
do not express CD133. In contrast, mature endothelial
cells (ECs) usually do not express VEGFR-2 [7] while
CD34 is first of all present in the vascular bed of lym-
phatic organs and all post-capillary venules [1]. 
Cancer expanding angiogenic blood vessels are not
only crucial for maintaining the tumour growth [8] but,
most likely, due to their embryonal-derived activity,
they enable the passage of cancer cells through their
wall (tumour cell invasion). In this way, the vascular
bed seems to cooperate with stromal and tumour cells
in early phase of metastases promoting. 
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Abstract: To evaluate the immunohistochemical expression of VEGF-C, CD34 and VEGFR-2 in cancer tissue of children
diagnosed with stadium 4 neuroblastoma (NB) and correlate their presence with the survival rate of children diagnosed with
that stage of the disease. Eighteen children assigned to stadium 4 composed the study group. Fourteen patients (allocated to
stadium 3) formed a control group. VEGF-C, CD34 and VEGFR-2 expressions were evaluated by immunohistochemical
assay. Consecutive slides incubated with anti-CD34 and anti-VEGFR-2 antibodies revealed that the two markers were co-
localized within endothelial layer of the blood vessels. On the other hand, VEGF-C was expressed exclusively in tumour
cells. As demonstrated by Fisher's exact test, the risk of NB treatment failure (progression or relapse) as well as tumour relat-
ed death, when all the patients were considered, was found to be significant in VEGF-C positive patients. VEGF-C expres-
sion in NB constitutes a potent risk factor and may direct future anti-angiogenic treatment strategy. The proximity of VEGF-
C and CD34/VEGFR-2 of NB could be the equivalent of a potentially interesting VEGF-C fashion involving a tumour cell
invasion into the blood vessels in an early phase of metastases promoting.
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An adequate model in such research could be neu-
roblastoma (NB) – the second most common solid
malignancy of childhood after brain tumours, account-
ing for 7 – 10% of all paediatric neoplasms [9]. About
40% of NBs arise in the adrenal medulla. The rest of
them are located first of all in the paravertebral region
of the abdomen (25%) and posterior mediastinum
(15%). 
Histologically, classic NBs are composed of small,
primitive-appearing cells with dark nuclei, scant cyto-
plasm and poorly defined cell borders growing in solid
sheets [10]. The loosely arranged stromal cells, situat-
ed among foci of small, blue and round cells, are usu-
ally fibrocystic or myxoid in nature. They are accom-
panied by well organised vasculature [9]. Metastases,
when develop, appear early and widely [11]. They
have a pronounced tendency to spread through the
bloodstream and involve the liver, lungs, bone marrow
and bones. The International Neuroblastoma Staging
System includes following stadia: 1, 2A and 2B, 3, 4
and 4S [10,12]. The first one (with the localised
tumour removed in toto) stadia 2A and 2B (localised
tumour with incomplete gross resection but non-adher-
ent to lymph nodes) as well as the stadium 4S
(localised tumour, as defined for stadia 1 and 2, with
dissemination limited to skin or liver or bone marrow
in children < 1 yr) [13, 14] are relatively rare in clini-
cal practice in Poland. The most common are stadium
3 (malignancy involving the surrounding lymphatic
nodes) and stadium 4 (like the previous one but with
distant metastases) [12]. 
The course of NB is extremely variable.
Unfavourable prognostic factors involve the age >1 yr,
stadia 3 and 4 (except of 4S), high mitotic rate [15],
diploidy, N-myc amplification [16-18], partial gain of
the distal long arm of chromosome 17 [16], deletion of
the distal short arm of chromosome 1 [19], high
expression of telomerase and certain neuropeptide
markers expression [20-23]. Similarly, the vessel den-
sity in NB correlates with tumour stage and outcome
[24]. Expression of angiogenic factors such as VEGF-
A, VEGF-C, VEGF-D have been demonstrated in NB
in vitro and in vivo suggesting their contribution to
tumour progression and metastasis [25, 26]. Interest-
ingly, all of them can bind the same type of receptor –
VEGFR-2 (a kinase-insert domain receptor,
KDR/foetal liver kinase, Flk-1). Except of being
reported on EPCs, it is considered to be the major sig-
nalling receptor for VEGF-C [27] – a growing factor
reported recently as a chief protein in NB lymphangio-
genesis [26]. In this way VEGFR-2 appears to be not
only a common factor coupling maturation of EPCs
and growth of blood vessels but also an element bind-
ing the activities of VEGF-A165 and VEGF-C.
In line with the above, the present studies aimed to
evaluate the immunohistochemical expression of
VEGF-C as well as the markers of late endothelial pro-
genitor cells (CD34 and VEGFR-2) in cancer tissue of
children diagnosed with stadium 4 neuroblastoma and
correlate their presence with the survival rate of chil-
dren diagnosed with that stage of the disease.
Patients and methods
Patients. During the period 1/1/1997 – 12/31/2006, 32 patients
with NB were surgically treated and administered chemotherapy in
the Department of Pediatric Oncology, Haematology and Trans-
plantology, Poznan University of Medical Sciences in Poland. The
research protocol was approved by the Ethical Commission of the
University. 
Eighteen children, aged 3 – 16, were assigned to stadium 4
(study group), the rest (allocated to stadium 3) composed a control
group (aged 3 – 17). Unfortunatelly, no children diagnosed with
stadium 1 or 2 NB was hospitalised in mentioned above time. 
The treatment protocol was based on experience of Study
Group of Japan for Treatment of Advanced Neuroblastoma,
Tokyo, Japan [28]. According to that program, recommended by
Polish Pediatric Solid Tumours Group in last 10 years, all the
children who were suspected of having neuroblastoma (radiolog-
ical examinations followed by serum dopamine and urine vanil-
lylmandelic acid evaluations) were initially treated with 4-6 sub-
sequent combinations of (1) cyclophosphamide // adriamycin //
carboplatin (1200 mg/m2 // 50 mg/m2 // 450 mg/m2) and (2)
cyclophosphamide // etoposide // cisplatin (1200 mg/m2 x2 // 500
mg/m2 // 125 mg/m2). Such a procedure was recommended in
order to improve the conditions for surgery. It must be empha-
sized that initial biopsy in this case was regarded that time as
inappropriate. After that inductive chemotherapy, the tumour
mass was surgically removed and tumour tissues were fixed in
Bouin´s solution for 24 hours at room temperature and subse-
quently embedded in paraffin.
Immunocytochemistry. In order to demonstrate the presence of
VEGF-C, VEGFR-2 and CD34 in tumour cells, an indirect
immunocytochemical procedure (the streptavidin-biotin complex
method with the use of horseradish peroxidase, StreptABCom-
plex/HRP) was performed using monoclonal mouse anti-human
antibodies against VEGF-C (H-190; Santa Cruz Biotechnology,
Heidelberg, Germany, sc-9047, diluted 1:100) and VEGFR-2 (pKo
R, 34a; diluted 1:100, a kind gift from Prof. K.C. Gatter, Universi-
ty of Oxford, UK) [29] as well as CD34 (Santa Cruz Biotechnolo-
gy, Heidelberg, Germany; sc-19587, diluted 1:100). Early EPCs
and mitotic activity of cancer cells was defined by expressions of
CD133 and Ki67. Their detection involved the use of rabbit and
mouse antibodies against human CD133 and Ki67 respectively (H-
284; Santa Cruz Biotechnology, Heidelberg, Germany, sc-30220,
diluted 1:50; Dako, Copenhagen, Denmark, M 7187, diluted
1:100). Heat-induced antigen demasking pre-treatment was also
carried out (Target Retrieval Solution, Dako S 1699) [30,31]. The
activity of endogenous peroxidase was blocked by 30 min pre-
incubation in 3% hydrogen peroxide. Following incubation with
the primary antibody for 24 h at 4°C, the specimens were treated
for 1 h at room temperature with biotin-conjugated goat anti-
mouse IgG (diluted 1:300; Sigma, Munich, Germany). Subse-
quently, the sections were incubated with an ABC reagent (Vectas-
tatin, Elite; Vector, Burlingame, CA, USA) for 45 min at room
temperature. The activity of peroxidase was detected by the use of
0.5% 3,3'-diaminobenzidine in Tris/HCl (pH=7.6) containing 0.3%
H2O2. 
Negative controls were performed by using normal mouse IgG
at the same concentrations as primary antibodies (Dako, Denmark,
X 0931, diluted 1:100) or phosphate buffer saline (PBS). Addi-
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tionally, to further confirm VEGF-C and VEGFR-2 antibodies speci-
ficity, blocking peptides were used (VEGF mBA-165; Santa Cruz,
Heidelberg, Germany, sc-4571; concentrated 10ng/ml and sVEGFR-
2-FC Chimera; RDI, Research Diagnostics, INC, Concord, MA,
USA, RDI-S01005; concentrated 30ng/ml). Primary antibodies were
incubated with their specific blocking peptides for 2h at room tem-
perature and then incubated with neuroblastoma tissues.
The reactions were observed with a Nikon Optiphot-2 light
microscope and documented using a CCD camera (Baumer
Optronic, arc6000c, Radeberg, Germany).
Finally, the analysis was performed blind on coded samples.
Quantitative and statistical analyses. Based on the immunohis-
tochemical results, which were analysed through the use of
Microimage (Olympus) morphometric software, the content of
reaction-positive cells was determined by comparing the number
of immunopositive cells with the total number of nucleated cells.
Changes in antigen distribution were evaluated measuring the area
of marker expression on each colour image by using the 'eye-drop-
per' tool as previously reported [21]. The estimates of CD34,
VEGFR-2 and VEGF-C expressions were subjected to mathemati-
cal analysis in order to examine changes of these markers in study
and control groups. These differences were then evaluated by a
one-way analysis of variance test (ANOVA). To determine the sig-
nificances between group means in the analysis of variance, the
nearest significant difference test (Tukey test) was used as the mul-
tiple comparison analysis. Significance was set at p<0.05 [32].
On the other hand, the Fisher's exact test, due to extremely lim-
ited number of patients, was employed to compare the frequencies
of disease progressions and tumour related deaths in the VEGF-C
positive and VEGF-C negative patients. Significance was defined
at p<0.05 [32]. 
Results
Clinical observation
During the observation period (the mean overall fol-
low-up interval was 17 months) clinical progression
(defined as radiological and histological confirmed
local relapse of malignancy or the appearance of dis-
tant metastases) was noted in 12 children from the
study group and 4 patients composing the control
group (no distant metastases in these subjects). Twelve
of them (10 allocated to study group and 2 of control
group) died due to the direct effect of metastases
(tumour related death). At the end of the observation
period, 20 children were still alive.
Immunohistochemical expressions of CD34,
VEGFR-2 and VEGF-C in tumour tissue
Consecutive slides incubated with anti-CD34 (Fig. 1a)
and anti-VEGFR-2 (Fig. 1b) antibodies revealed that
the two markers were co-localized. These immunopos-
itive cells were situated exclusively within endothelial
layer of the blood vessels located within tumour foci as
well as among loosely arranged stromal cells. Interest-
ingly, the same immunoreactivity and localisation was
observed in all the stadium 4 (study group) and stadi-
um 3 children (control group, p=0.97, ns). Moreover,
endothelial cells composing original (not angiogenic)
blood vessels performed significantly lower expres-
sion of both CD34 and VEGFR-2 as compared to
blood vessels (angiogenic) present within tumour foci
(p=0.003 and p=0.0056 consequently). No CD133
expression was found within all studied specimens
(data not shown).
According to VEGF-C expression, it was present in
a single child qualified to stadium 3 NB and in 15/18
children from the study group. VEGF-C positive cells
in these patients consisted exclusively of blasts; no
VEGF-C expression was found in any of the endothe-
lial cells (Fig. 1c and Fig. 2), nor within stromal cells
(Fig. 1c). 
Consecutive slides incubated with anti-VEGF-C
and anti-CD34 or anti-VEGFR-2 antibodies revealed
that the latter endothelial markers were situated in the
closest proximity to VEGF-C immuno-positive aggre-
gations of cancer cells (Fig. 1a-c). Additionally, blood
vessels stained with CD34 and VEGFR-2 in stadium 
4 patients, were significantly active angiogenic struc-
tures since tumour metastatic cells (expressing Ki67,
Fig. 1d) were clearly visible within their lumen.
Detailed information is present in Table 1. 
Finally, the specific blocking peptides (data not
shown) inhibited the staining described above. Identi-
cal results were obtained by using normal mouse IgG
or PBS.
Statistical analysis
As demonstrated by Fisher's exact test (Table 2), the
risk of NB treatment failure (progression or relapse) as
well as tumour related death, when all the patients
were considered (regardless of NB stage), was found
to be significant in VEGF-C positive patients
(p=0.0061 and p=0.0003 consequently). Comparative-
ly, the risk of metastases was found to be significant in
patients expressing VEGF-C in tumour blast cells
(p<0.0001). The expression of CD34 and VEGFR-2 by
ECs had no prognostic value. 
On the other hand, as shown in Table 2, the risk of
neuroblastoma relapse or death was not significant,
when stadium 3 or stadium 4 patients were considered
separately (although the risk of tumour related death in
stadium 4 patients could be regarded as nearly signifi-
cant; p=0.0686)
Statistical analysis of those patients in whom no
treatment failure was noted during the observation
period revealed that the probability of NB remission
was significantly higher in these study participants
with VEGF-C -negative blasts (p=0.0061).
Discussion
It must be emphasized in particular that all the patients
at the time of surgery had tumour tissue affected more
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or less by chemotherapy; however, this was the only
way to obtain that time histological material. Natural-
ly, it was not 'virgin' tissue, but there were still large
areas of neoplastic tissue free of necrosis, haemor-
rhage or fibrosis, as can be seen in the provided pic-
tures. In our opinion such a treatment primarily
decreased tumour volume by reduction at the periph-
ery and had less effect on the central portion from
which all the tissue blocks were obtained. 
The first observation related to the present study is
that NB blood vasculature is mainly composed of late
EPCs. These cells expressing both CD34 and VEGFR-
2 might facilitate tumour cells invasion into blood ves-
sels when accompanied by extra-vascular secretion of
VEGF-C. 
CD34 – a proteoglycan found on endothelial and
bone marrow cells belongs to the group of endothelial
ligands which can bind L-selectin (CD62L). This type
of selectin, expressed primarily on lymphocytes,
serves as a homing receptor for leukocytes to cytokine-
activated cells at sites of inflammation [33]. Physio-
logically endothelial cells express CD34 in lymphatic
organs and post-capillary venules which initiate the
process of diapedesis [34]. Our results highlight the
presence of CD34 positive ECs in all the blood vessels
of tumour stroma in all the neuroblastoma children
(regardless of patients age and disease stage). CD34-
positive cells were most likely not present in endothe-
lial cells of lymphatic vessels which must have been
VEGFR-2 negative as referred to observation on con-
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Fig. 1. Immunohistochemistry of CD34 (a), VEGFR-2 (b) and one of its ligand VEGF-C (c) as well as Ki67 (d) in neuroblastoma tumour
of a 5-year old child. (a) CD34 positive ECs in blood vessels of stromal phase of the tumour (arrowhead) and a few CD34 positive ECs
in a single vein of neuroblastoma stromal component (arrow). (b) consecutive slide incubated with anti-VEGFR-2 antibodies reveals that
the two markers (CD34 and VEGFR-2) are co-localized; immunopositive cells are situated exclusively within endothelial layer of the
blood vessels located within tumour foci as well as among loosely arranged stromal cells; notice a few VEGFR-2 positive ECs in a sin-
gle vein of neuroblastoma stromal component (arrow). (c) VEGF-C immunoreactivity within tumour cells (arrow) and metastatic cells in
angiogenic blood vessels (arrowhead); no VEGF-C expression is found in any of the ECs. (d) immunohistochemical reaction for Ki67 is
present in tumour cells (arrows) and metastatic cells which are clearly visible within the lumen of angiogenic vessels (arrowhead). Scale
bar: 100 µm.
secutive slides. It is highly probable that CD34-posi-
tive ECs or EPCs at sites of neoplastic tissues empow-
er cancer cells to cross the wall of the blood vessels. It
was not yet clear, however, what is the trigger mecha-
nism for this process. In our opinion it could be
explained in part by the presence of VEGFR-2 in EPCs
and one of its ligand – VEGF-C in tumour cells.
VEGFR-2 binds VEGF, VEGF-C and VEGF-D [27].
Although the binding affinity of VEGF towards
VEGFR-2 is lower than that for VEGFR-1, selective
activation of VEGFR-1 and VEGFR-2 has shown that
VEGFR-2 is the primary receptor transmitting VEGF
and VEGF-C signals in endothelial cells [35-37]. The
expression of VEGFR-2 is autoregulated: VEGF, VEGF-
C and VEGF-D up-regulate the expression of VEGFR-2
[38,39]. VEGFR-2 expression is down-regulated in the
adult blood vascular ECs, and is again up-regulated in
the endothelium of angiogenic blood vessels [40]. 
The mature form of VEGF-C induces mitogenesis,
migration and survival of ECs [41]. During develop-
ment, VEGF-C is expressed along with its receptor
VEGFR-3 predominantly in regions where lymphatic
vessels develop [42,43]. The expression then decreases
in most tissues, remaining high in the lymph nodes [44].
Recently VEGF-C has been reported to play a cru-
cial role in the regulation of lymphangiogenesis in
human neuroblastoma [26]. It did not act as a factor
promoting tumour blast cells growth but cooperated in
development of VEGFR-3 positive lymphatic vessels.
This study suit our observation in which we have not
detected VEGFR-2 expression in cancer cells. We
have evaluated, however, the presence of VEGFR-2
positive angiogenic blood vessels which, undoubtedly
together with lymphatic vessels, compose the metasta-
tic capacity of NB. As shown on Fig. 1d, these angio-
genic blood vessels are metastatically active structures
since Ki67 positive tumour cells were clearly visible
inside their lumen.
Although VEGF-C is not essential for the develop-
ment of blood vessels unlike its receptor VEGFR-2, it
is a common factor which combine angio- and lym-
phangiogenesis as well as recruiting EPCs from the
bone marrow (30% homology to VEGF165). In a few
experimental models, tumour cells overexpressing
VEGF-C or VEGF-D induced peritumoural and in
some cases stromal lymphangiogenesis and tumour cell
invasion into lymphatic vessels [40,45,46]. Interesting-
ly, also some recently published data indicate that NB-
associated endothelial microvessels can originate
directly from tumour cells [47]. In our observation, the
similar VEGF-C related activity could be present also
in angiogenic NB blood vessels. VEGF-C which is
released in the closest proximity of these blood vessels
not only contributes in endothelial growth but also
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Table 1. Clinical characteristics and results of CD34/VEGFR-2 and VEGF-C determination in children diagnosed with neuroblastoma. 
*according to The International Neuroblastoma Staging System [12]; VEGFR – vascular endothelial growth factor receptor; VEGF-C – vascular endothe-
lial growth factor C
Fig. 2. Immunohistochemistry of VEGF-C in neuroblastoma
tumour of a 4-year old child. Strong VEGF-C immunoreactivity is
observed exclusively within cytoplasm of cancer cells. Microves-
sel bed of the tumour is VEGF-C negative (arrow). Scale bar: 50
µm.
Table 2. Correlation between treatment failure (relapse). tumour
related death and VEGF-C expression in cancer cells of children
with neuroblastoma (Fisher's exact test).
*according to The International Neuroblastoma Staging System [12];
VEGF-C = vascular endothelial growth factor C; (p value) statistically sig-
nificant if <0.05.
probably enables its activation promoting CD34-
dependent diapedesis of cancer cells. The process of
aggressive chemotherapy may then lead not only to
eradication of tumour cells but also to reducing of
bone marrow progenitor cells. The former impact of
bone marrow is definitely the undesirable side effect
but the latter one may result in reduction of EPCs
and, in fact, extenuation of tumour vascular potency.
From this point of view, the restriction of chemother-
apy regimen postulated recently in NB should be
accompanied by parallel anti-angiogenic treatment
directed against VEGFR-2.
The second observation in this research involves
VEGF-C potency as a facultative risk factor in this
disease. NB growth, as in all tumours larger than 1-2
mm, is strictly dependent on angiogenesis [7,48]. Up
to the present , the greatest attention in NB has been
directed at VEGF as well as its receptors VEGFR-1
and VEGFR-2 [49]. Still, there are few reports
describing the expression of VEGF-C in neuroblas-
toma tissue [26]. 
In our findings VEGF-C was expressed by all can-
cer cells in 15/18 children qualified to stadium 4 NB
and only in a single patient from the control group (sta-
dium 3). It may suggest that in spite of EPCs potency
in angiogenic NB blood vasculature it is VEGF-C
which independently triggers tumour cells invasion
into blood vessels. Thus it should be regarded as a
novel risk factor. In our preliminary, not-published yet
studies, we found that VEGF-C is also present in
microscopically normal bone marrow hematopoietic
cells in stadium 3 NB. It seems that these cells are
involved in early phase of homing the metastatic cells
in the bone marrow. In that way VEGF-C would be
engaged not only into formation of metastases at site
of tumour but also in their incorporation within distant
tissues. 
In conclusion, VEGF-C expression in neuroblas-
toma might constitute a novel risk factor and could
direct future anti-angiogenic treatment strategy. The
proximity of VEGF-C and CD34/VEGFR-2 in blast
cells and endothelial components of neuroblastoma
could be the equivalent of a potentially interesting
VEGF-C fashion involving a tumour cell invasion into
the blood vessels in an early phase of metastases pro-
moting.
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